Jupiter Neurosciences (JUNS) Assets Average (2024 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Assets Average of $4.1 million for Q4 2025, up 29.46% year-over-year from $3.1 million in Q4 2024, and up 24.39% quarter-over-quarter from $3.3 million in Q3 2025.
Jupiter Neurosciences (JUNS) Assets Average (2024 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Assets Average for 2 consecutive years, with $4.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 29.46% year-over-year to $4.1 million; the TTM figure through Dec 2025 stood at $4.1 million (up 29.46% YoY), while the FY2025 annual figure was $5.9 million, up 85.27% from the prior year.
- Assets Average climbed to $4.1 million in Q4 2025 per JUNS's latest filing, from $3.3 million in the prior quarter.
- Across five years, Assets Average topped out at $5.6 million in Q1 2025 and bottomed at $3.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Jupiter Neurosciences | 2.88 Mn | 1.36 Mn | 21,064.00 | 4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 4.47 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 3.14 Mn |